This trial will explore the maximum tolerated dose (MTD)of NKG2D CAR-NK cells in the treatment of platinum-resistant, relapsed epithelial ovarian cancer in a dose-escalation manner, and observe the clinical safety and efficacy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
18
Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
RECRUITINGDLT
Dose-Limiting Toxicity
Time frame: 28 days
MTD
Maximal Tolerable Dose
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.